Kancera reports that patient enrollment to the FRACTAL-study is completed and that top line results will be presented in Q3 2023

The FRACTAL-study is a phase IIa clinical study of KAND567 in myocardial infarction patients undergoing percutaneous coronary intervention. The study is conducted in collaboration with the British NHS Foundation, which is the sponsor of the study. The FRACTAL-study is being conducted at the Freeman Hospital in Newcastle and James Cook Hospital in Middlesbrough. The primary objective of the study is to evaluate safety and tolerability. The secondary objective is to evaluate evidence of KAND567’s treatment efficacy.

The initial objective was to enroll 60 study subjects in total. As enrollment has progressed well throughout 2022, Kancera and NHS Foundation decided in September 2022 to amend the study protocol to allow for recruitment of additional patients, in order to strengthen the study in terms of increased number of evaluable study subjects. Kancera now reports that patient enrollment has been completed and that a total of 71 patients have been recruited. As previously has been announced, Kancera aims to report top line data from the FRACTAL-study during Q3 2023.

About Kancera AB (publ)
Kancera is developing a new class of drugs for treatment of cancer and severe inflammatory diseases, that today are lacking effective treatments. Kancera’s main focus is to develop small molecule drug candidates based on the Fractalkine system. Fractalkine is a natural master regulator that with precision controls immune cells and cancer cells. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB (info@fnca.se) is the company’s Certified Adviser.

For further information:
Thomas Olin
Chief Executive Officer, Kancera AB
Tel: +46-73-620 40 01

Visit Kancera’s web page: https://www.kancera.com/en